United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension Transcript

SA Transcripts158.75K FollowersFollow5ShareSaveCommentsQ4: 2026-02-25 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallTranscriptEPS of $7.70 beats by $0.46 | Revenue of $790.20M (7.38% Y/Y) misses by $21.15M United Therapeutics Corporation (UTHR) Discusses Phase III ADVANCE OUTCOMES Clinical Trial Results in Pulmonary Hypertension March 2, 2026 8:30 AM EST Company Participants Harrison Silvers - Manager of Investor RelationsMartine Rothblatt - Founder, Chairman & CEO Conference Call Participants Derek SolumDaniel LachantAndreas Argyrides - Oppenheimer & Co. Inc., Research DivisionRoanna Clarissa Ruiz - Leerink Partners LLC, Research DivisionOlivia Brayer - Cantor Fitzgerald & Co., Research DivisionJiale Song - Jefferies LLC, Research DivisionLisa Walter - RBC Capital Markets, Research DivisionJason Gerberry - BofA Securities, Research DivisionTerence Flynn - Morgan Stanley, Research Division Presentation Operator Good morning, everyone, and welcome to the United Therapeutics Corporation Phase III ADVANCE OUTCOMES Clinical Trial Results Conference Call. My name is Jamie, and I will be your conference operator today. [Operator Instructions] Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Mr. Harry Silvers, Investor Relations Manager at United Therapeutics. Harrison SilversManager of Investor Relations Thank you, Jamie. Good day, everyone. It is my pleasure to welcome you to the United Therapeutics Corporation Phase III ADVANCE OUTCOMES Clinical Trial Results Conference Call. Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q, contain additional information on these risks and uncertainties. We assume no obligation to update forward-looking statements. Today's remarks may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for the